• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

导管原位癌(DCIS)分期升级的预测:病理因素相较于影像学风险因素的主导作用

Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.

作者信息

Choi Sunhyung, Park Bombi, Lee Eun-Gyeong, Lee Seeyoun, Kang Han-Sung, Jung So-Youn, Lee Dong-Eun, Han Jai-Hong

机构信息

Department of Surgery, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.

Department of Surgery, Center for Breast Cancer, National Cancer Center, Goyang, South Korea.

出版信息

Breast Cancer Res Treat. 2025 Oct;213(3):325-334. doi: 10.1007/s10549-025-07768-6. Epub 2025 Aug 1.

DOI:10.1007/s10549-025-07768-6
PMID:40748441
Abstract

PURPOSE

Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer with variable risk of upstaging to invasive carcinoma. Accurate preoperative risk stratification is critical to guide management decisions and minimize overtreatment. This study aimed to identify clinicopathological and imaging predictors of DCIS upstaging to invasive cancer.

METHODS

We conducted a retrospective analysis of 701 patients diagnosed with DCIS, among whom 200 (28.5%) were upstaged to microinvasive or invasive carcinoma. Logistic regression was used to evaluate the association between upstaging and various factors, including tumor size, nuclear grade, comedo necrosis, progesterone receptor (PR) negativity, human epidermal growth factor receptor 2 (HER2) overexpression, and mammographic findings.

RESULTS

Tumor size > 5 cm, comedo necrosis, PR negativity, and mammographic microcalcifications were independent predictors of upstaging. While HER2 overexpression was significant in univariate analysis, it was not retained in the multivariate model. Non-mass lesions on ultrasound and magnetic resonance imaging (MRI) were not significant predictors.

CONCLUSION

Integrating these markers into preoperative risk stratification models may improve individualized treatment planning and reduce overtreatment in patients with DCIS.

摘要

目的

导管原位癌(DCIS)是一种非浸润性乳腺癌,进展为浸润性癌的风险各异。准确的术前风险分层对于指导治疗决策和减少过度治疗至关重要。本研究旨在确定DCIS进展为浸润性癌的临床病理和影像学预测因素。

方法

我们对701例诊断为DCIS的患者进行了回顾性分析,其中200例(28.5%)进展为微浸润或浸润性癌。采用逻辑回归评估进展与各种因素之间的关联,这些因素包括肿瘤大小、核分级、粉刺样坏死、孕激素受体(PR)阴性、人表皮生长因子受体2(HER2)过表达以及乳腺X线摄影表现。

结果

肿瘤大小>5 cm、粉刺样坏死、PR阴性和乳腺X线摄影微钙化是进展的独立预测因素。虽然HER2过表达在单变量分析中具有显著性,但在多变量模型中未保留。超声和磁共振成像(MRI)上的非肿块性病变不是显著的预测因素。

结论

将这些标志物纳入术前风险分层模型可能会改善DCIS患者的个体化治疗方案并减少过度治疗。

相似文献

1
Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.导管原位癌(DCIS)分期升级的预测:病理因素相较于影像学风险因素的主导作用
Breast Cancer Res Treat. 2025 Oct;213(3):325-334. doi: 10.1007/s10549-025-07768-6. Epub 2025 Aug 1.
2
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.术前诊断为导管原位癌(DCIS)患者术后升级为浸润性导管癌(IDC)的临床病理预测因素:一项多机构回顾性队列研究。
Breast Cancer. 2021 Jul;28(4):896-903. doi: 10.1007/s12282-021-01225-0. Epub 2021 Feb 18.
3
[Comparison of clinicopathological and MRI imaging features between ductal carcinoma in situ with microinfiltration and ductal carcinoma in situ of the breast].乳腺导管原位癌伴微浸润与乳腺导管原位癌的临床病理及MRI影像学特征比较
Zhonghua Zhong Liu Za Zhi. 2025 Aug 23;47(8):726-733. doi: 10.3760/cma.j.cn112152-20231007-00168.
4
Preoperative MRI to Predict Upstaging of DCIS to Invasive Cancer at Surgery.术前MRI预测手术时导管原位癌升级为浸润性癌的情况。
Ann Surg Oncol. 2025 May;32(5):3234-3243. doi: 10.1245/s10434-024-16837-x. Epub 2025 Jan 28.
5
MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial).基于MRI的影像组学特征用于多中心环境下导管原位癌的风险分层(ECOG-ACRIN E4112试验)
Radiology. 2025 Apr;315(1):e241628. doi: 10.1148/radiol.241628.
6
A retrospective study evaluating surgical upstaging rates in low-risk DCIS patients meeting the eligibility criteria for active surveillance trials.一项回顾性研究,评估符合主动监测试验纳入标准的低风险导管原位癌(DCIS)患者的手术分期上调率。
Eur J Surg Oncol. 2025 Jul;51(7):109716. doi: 10.1016/j.ejso.2025.109716. Epub 2025 Feb 26.
7
Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.浸润性导管癌及并存的导管原位癌中HER2表达的定量评估。
Breast Cancer Res Treat. 2025 Jul 18. doi: 10.1007/s10549-025-07781-9.
8
Clinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.导管原位癌的临床病理特征及后续浸润性乳腺癌的风险:一项基于人群的多中心队列研究
Breast Cancer Res Treat. 2025 Apr;210(3):615-625. doi: 10.1007/s10549-024-07599-x. Epub 2025 Jan 20.
9
Eco-Evolutionary Guided Pathomic Analysis Detects Biomarkers to Predict Ductal Carcinoma In Situ Upstaging.生态进化引导的病理分析检测生物标志物以预测原位导管癌分期升级。
Cancer Res. 2025 Jun 2;85(13):2537-2547. doi: 10.1158/0008-5472.CAN-24-2070.
10
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.乳腺导管原位癌:发病率、治疗和结局的系统评价。
J Natl Cancer Inst. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13.

本文引用的文献

1
Should low-risk DCIS lose the cancer label? An evidence review.低危 DCIS 是否应该去掉“癌症”标签?一项证据回顾。
Breast Cancer Res Treat. 2023 Jun;199(3):415-433. doi: 10.1007/s10549-023-06934-y. Epub 2023 Apr 19.
2
The clinical significance of HER2 expression in DCIS.HER2表达在导管原位癌中的临床意义。
Med Oncol. 2022 Nov 9;40(1):16. doi: 10.1007/s12032-022-01876-9.
3
DCIS: Risk Assessment in the Molecular Era.DCIS:分子时代的风险评估。
Semin Radiat Oncol. 2022 Jul;32(3):189-197. doi: 10.1016/j.semradonc.2022.01.005.
4
Advances and controversies in management of breast ductal carcinoma in situ (DCIS).乳腺导管原位癌(DCIS)治疗的进展与争议。
Eur J Surg Oncol. 2022 Apr;48(4):736-741. doi: 10.1016/j.ejso.2021.10.030. Epub 2021 Nov 9.
5
Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.前哨淋巴结活检在导管原位癌患者中的必要性:一项回顾性分析。
BMC Surg. 2021 Mar 22;21(1):159. doi: 10.1186/s12893-021-01170-x.
6
Predictors of invasive disease in patients preoperatively diagnosed with ductal carcinoma without stromal invasion, with breast magnetic resonance imaging (MRI) and ultrasound (US).通过乳腺磁共振成像(MRI)和超声(US)对术前诊断为无间质浸润的导管癌患者进行浸润性疾病预测指标的研究。
Breast Cancer. 2021 Mar;28(2):398-404. doi: 10.1007/s12282-020-01187-9. Epub 2020 Nov 16.
7
Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2018.韩国男性和女性癌症筛查率趋势:2004-2018 年韩国国家癌症筛查调查结果。
Cancer Res Treat. 2021 Apr;53(2):330-338. doi: 10.4143/crt.2020.263. Epub 2020 Oct 20.
8
Predictors for upstaging of ductal carcinoma (DCIS) to invasive carcinoma in non-mass-type DCIS.非肿块型导管原位癌(DCIS)进展为浸润性癌的分期上调预测因素。
Mol Clin Oncol. 2020 Jul;13(1):67-72. doi: 10.3892/mco.2020.2036. Epub 2020 Apr 27.
9
Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors.乳腺导管原位癌:重点关注作为预测性预后因素的放射学和形态学特征的最新进展
Cancers (Basel). 2020 Mar 6;12(3):609. doi: 10.3390/cancers12030609.
10
An Updated Nomogram for Predicting Invasiveness in Preoperative Ductal Carcinoma In Situ of the Breast.术前乳腺导管原位癌侵袭性的列线图预测更新。
Yonsei Med J. 2019 Nov;60(11):1028-1035. doi: 10.3349/ymj.2019.60.11.1028.